Description

IVER-ASH 12 MG

Indications

IVER-ASH 12 MG is primarily indicated for the treatment of various parasitic infections, particularly those caused by helminths (worms). It is commonly used in the management of conditions such as onchocerciasis (river blindness), lymphatic filariasis, and strongyloidiasis. The medication is also utilized in the treatment of scabies and certain types of skin infections caused by parasites. Its broad-spectrum antiparasitic activity makes it a valuable option in both endemic and non-endemic regions.

Mechanism of Action

The active ingredient in IVER-ASH 12 MG is ivermectin, which belongs to the class of drugs known as antiparasitics. Ivermectin works by binding to specific channels in the membranes of the parasites. It enhances the release of gamma-aminobutyric acid (GABA), leading to paralysis and death of the parasites. Additionally, ivermectin disrupts the function of glutamate-gated chloride channels, which are essential for the survival of nematodes and arthropods. This dual action effectively eliminates the parasites from the host organism.

Pharmacological Properties

IVER-ASH 12 MG exhibits a pharmacokinetic profile characterized by rapid absorption following oral administration. Peak plasma concentrations are typically achieved within 4 to 5 hours. The drug is extensively distributed throughout the body, with a volume of distribution of approximately 4 to 6 L/kg. Ivermectin is primarily metabolized in the liver and has a half-life of about 12 to 36 hours, depending on individual patient factors. The drug is excreted mainly through feces, with a smaller percentage eliminated in urine. This pharmacological profile supports its efficacy in treating various parasitic infections.

Contraindications

IVER-ASH 12 MG is contraindicated in individuals with a known hypersensitivity to ivermectin or any of the excipients in the formulation. It should not be administered to patients with conditions that may be exacerbated by the drug’s effects, such as certain neurological disorders. Additionally, caution is advised when prescribing IVER-ASH to pregnant or breastfeeding women, as the safety of ivermectin in these populations has not been fully established. Patients with severe liver impairment should also avoid this medication due to the potential for increased drug accumulation and toxicity.

Side Effects

Like all medications, IVER-ASH 12 MG may cause side effects. Commonly reported adverse reactions include dizziness, nausea, diarrhea, and fatigue. Some patients may experience skin rashes or itching. In rare cases, more severe reactions such as hypotension, seizures, or allergic reactions may occur. Patients are advised to report any unusual symptoms or side effects to their healthcare provider promptly. Monitoring for adverse effects is particularly important in patients with pre-existing health conditions or those taking multiple medications.

Dosage and Administration

The recommended dosage of IVER-ASH 12 MG varies depending on the specific parasitic infection being treated. For onchocerciasis, the typical dose is 150 micrograms per kilogram of body weight, administered as a single oral dose. For lymphatic filariasis, a single dose of 200 micrograms per kilogram is often sufficient. It is essential to follow the prescribing physician’s instructions regarding dosage and frequency of administration. Patients should take the medication with water on an empty stomach for optimal absorption. In cases of reinfection or persistent symptoms, retreatment may be necessary.

Interactions

IVER-ASH 12 MG may interact with other medications, potentially altering their effectiveness or increasing the risk of side effects. Notably, the use of ivermectin with other drugs that affect the central nervous system, such as benzodiazepines or barbiturates, may enhance sedative effects. Additionally, caution should be exercised when combining IVER-ASH with medications that are metabolized by the liver, as this may lead to increased plasma levels of either drug. It is crucial for patients to inform their healthcare provider of all medications they are currently taking, including over-the-counter drugs and supplements, to avoid potential interactions.

Precautions

Before initiating treatment with IVER-ASH 12 MG, a thorough medical history and physical examination should be conducted. Special precautions should be taken in patients with a history of liver disease, as they may be at increased risk for adverse effects. Furthermore, patients with compromised immune systems or those who are elderly may require closer monitoring during treatment. It is also essential to educate patients about the signs of potential side effects and the importance of adhering to the prescribed treatment regimen to ensure the best possible outcomes.

Clinical Studies

Clinical studies have demonstrated the efficacy of IVER-ASH 12 MG in treating various parasitic infections. In a randomized controlled trial involving patients with onchocerciasis, treatment with ivermectin resulted in a significant reduction in microfilarial density and improved clinical outcomes. Another study assessing the effectiveness of ivermectin for lymphatic filariasis showed that a single dose could effectively reduce the number of circulating filarial antigens. These studies support the use of IVER-ASH as a first-line treatment option for these conditions, highlighting its role in public health initiatives aimed at controlling parasitic diseases.

Conclusion

IVER-ASH 12 MG is a potent antiparasitic medication indicated for the treatment of various helminthic infections. Its mechanism of action, pharmacological properties, and clinical efficacy make it a valuable tool in the management of these diseases. However, careful consideration of contraindications, potential side effects, and drug interactions is essential for safe and effective use. Patients should be educated about the importance of adherence to the prescribed regimen and the need for follow-up care to monitor treatment outcomes. Overall, IVER-ASH represents a critical component in the fight against parasitic infections globally.